You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlordiazepoxide
Accession NumberDB00475  (APRD00682)
TypeSmall Molecule
GroupsApproved, Illicit
Description

An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. [PubChem]

Structure
Thumb
Synonyms
7-chloro-2-Methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide
CDP
Chloradiazepoxide
Chlordiazepoxide base
Chlordiazepoxidum
Clopoxide
Helogaphen
Libritabs
Methaminodiazepoxide
Multum
Risolid
Silibrin
Tropium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlordiazepoxidecapsule5 mgoralAa Pharma Inc1981-12-31Not applicableCanada
Chlordiazepoxidecapsule25 mgoralAa Pharma Inc1981-12-31Not applicableCanada
Chlordiazepoxidecapsule10 mgoralAa Pharma Inc1981-12-31Not applicableCanada
Chlordiazepoxide Cap 10mgcapsule10 mgoralPro Doc Limitee1969-12-312010-07-13Canada
Chlordiazepoxide Cap 5mgcapsule5 mgoralPro Doc Limitee1976-12-312009-07-23Canada
Chlordiazepoxyde 25 Capcapsule25 mgoralDuchesnay Inc1981-12-312003-07-18Canada
Chlordiazepoxyde Cap 10mgcapsule10 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Chlordiazepoxyde HCl Cap 25mgcapsule25 mgoralPro Doc Limitee1978-12-312010-07-13Canada
Corax Cap 10mgcapsule10 mgoralIcn Canada Ltd.1968-12-311998-08-13Canada
Corax Cap 25mgcapsule25 mgoralIcn Canada Ltd.1973-12-311998-08-13Canada
Corax Cap 5mgcapsule5 mgoralIcn Canada Ltd.1974-12-311998-08-13Canada
Medilium Cap 10 10mgcapsule10 mgoralMedic Laboratory LtÉe1970-12-311996-09-09Canada
Medilium Cap 5mgcapsule5 mgoralMedic Laboratory LtÉe1971-12-311996-09-09Canada
Novo-poxide 10mgcapsule10 mgoralNovopharm Limited1968-12-312005-08-10Canada
Novo-poxide 25mgcapsule25 mgoralNovopharm Limited1970-12-312005-08-10Canada
Novo-poxide 5mgcapsule5 mgoralNovopharm Limited1970-12-312005-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlordiazepoxidecapsule25 mg/1oralDIRECT RX2016-03-04Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-10-31Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mg/1oralGolden State Medical Supply, Inc.2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule10 mg/1oralbryant ranch prepack1990-09-30Not applicableUs
Chlordiazepoxide Hydrochloridecapsule10 mg/1oralBarr Laboratories Inc.1990-09-30Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralA S Medication Solutions Llc1976-07-02Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-06Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralPhysicians Total Care, Inc.1993-03-24Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-05-10Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mg/1oralGolden State Medical Supply, Inc.2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mg/1oralAv Kare, Inc.2002-09-26Not applicableUs
Chlordiazepoxide Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.1994-12-09Not applicableUs
Chlordiazepoxide Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-08-11Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mg/1oralGolden State Medical Supply, Inc.2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mg/1oralAv Kare, Inc.2002-09-26Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralA S Medication Solutions Llc1976-07-02Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2011-08-01Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralCardinal Health2011-04-01Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mg/1oralAv Kare, Inc.2002-09-26Not applicableUs
Chlordiazepoxide Hydrochloridecapsule10 mg/1oralMylan Institutional Inc.1996-03-05Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated25 mg/1oralSolco Healthcare US LLC2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule10 mg/1oralCardinal Health2011-04-01Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralContract Pharmacy Services Pa2010-04-07Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralBarr Laboratories Inc.1976-07-02Not applicableUs
Chlordiazepoxide Hydrochloridecapsule5 mg/1oralMylan Institutional Inc.1995-12-08Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated10 mg/1oralSolco Healthcare US LLC2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule5 mg/1oralCardinal Health2011-04-01Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralREMEDYREPACK INC.2012-03-14Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralbryant ranch prepack2010-12-06Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralTYA Pharmaceuticals1976-07-02Not applicableUs
Chlordiazepoxide Hydrochloridecapsule5 mg/1oralBarr Laboratories Inc.1976-07-01Not applicableUs
Chlordiazepoxide Hydrochloridecapsule25 mg/1oralMylan Institutional Inc.1994-05-06Not applicableUs
Chlordiazepoxide Hydrochloridecapsule, gelatin coated5 mg/1oralSolco Healthcare US LLC2010-05-15Not applicableUs
Chlordiazepoxide Hydrochloridecapsule5 mg/1oralPhysicians Total Care, Inc.1993-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AngirexNot Available
EleniumPolfa Tarchomin
KlopoxidNycomed
LibriumAbbott
NapotonNot Available
RadepurAWD
RisolidActavis
SilibrinNot Available
SonimenNot Available
Brand mixtures
NameLabellerIngredients
ChloraxAa Pharma Inc
Chlordiazepoxide and Amitriptyline HClPar Pharmaceutical Inc
Chlordiazepoxide and Amitriptyline HydrochlorideMylan Pharmaceuticals Inc.
Chlordiazepoxide Hydrochloride and Clidinium BromideAcella Pharmaceuticals, LLC
Chlordiazepoxide Hydrochloride/clidinium BromideAv Kare, Inc.
Corium CapIcn Canada Ltd.
LibraxValeant Pharmaceuticals International
Nu-chlorax Capsules USPNu Pharm Inc
Pro ChloraxPro Doc Limitee
Salts
Name/CASStructureProperties
Chlordiazepoxide Hydrochloride
438-41-5
Thumb
  • InChI Key: PRNVHVUEIITLRV-UHFFFAOYSA-N
  • Monoisotopic Mass: 335.059217531
  • Average Mass: 336.216
DBSALT000632
Categories
UNII6RZ6XEZ3CR
CAS number58-25-3
WeightAverage: 299.755
Monoisotopic: 299.082539792
Chemical FormulaC16H14ClN3O
InChI KeyInChIKey=ANTSCNMPPGJYLG-UHFFFAOYSA-N
InChI
InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)
IUPAC Name
7-chloro-2-(methylamino)-5-phenyl-3H-1,4λ⁵-benzodiazepin-4-one
SMILES
CNC1=NC2=C(C=C(Cl)C=C2)C(C2=CC=CC=C2)=N(=O)C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Imidolactam
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Nitrone
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organic salt
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
PharmacodynamicsChlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a "taming" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.
Mechanism of actionChlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationChlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.
Half life24-48 hours
ClearanceNot Available
ToxicityLD50=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9758
Caco-2 permeable+0.5868
P-glycoprotein substrateSubstrate0.6705
P-glycoprotein inhibitor INon-inhibitor0.521
P-glycoprotein inhibitor IINon-inhibitor0.7434
Renal organic cation transporterNon-inhibitor0.5502
CYP450 2C9 substrateNon-substrate0.6991
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.7564
CYP450 2C9 inhibitorNon-inhibitor0.6038
CYP450 2D6 inhibitorNon-inhibitor0.7862
CYP450 2C19 inhibitorNon-inhibitor0.5
CYP450 3A4 inhibitorInhibitor0.7067
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6372
Ames testNon AMES toxic0.593
CarcinogenicityNon-carcinogens0.7108
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8520 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9198
hERG inhibition (predictor II)Non-inhibitor0.8828
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Valeant pharmaceuticals international
  • Abbott laboratories pharmaceutical products div
  • Rachelle laboratories inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Barr laboratories inc
  • John j ferrante
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lederle laboratories div american cyanamid co
  • Mm mast and co
  • Mylan pharmaceuticals inc
  • Parke davis div warner lambert co
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Alra laboratories inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg
Capsuleoral25 mg
Capsuleoral5 mg
Tabletoral
Tablet, film coatedoral
Capsuleoral10 mg/1
Capsuleoral25 mg/1
Capsuleoral5 mg/1
Capsule, gelatin coatedoral10 mg/1
Capsule, gelatin coatedoral25 mg/1
Capsule, gelatin coatedoral5 mg/1
Capsuleoral
Prices
Unit descriptionCostUnit
Librax 2.5-5 mg capsule6.5USD capsule
Librax capsule5.78USD capsule
Librium 25 mg capsule2.14USD capsule
Limbitrol DS 10-25 mg tablet1.93USD tablet
Librium 10 mg capsule1.61USD capsule
Librium 5 mg capsule0.84USD capsule
Chlordiazepoxide 25 mg capsule0.72USD capsule
ChlordiazePOXIDE HCl 25 mg capsule0.32USD capsule
ChlordiazePOXIDE HCl 10 mg capsule0.31USD capsule
ChlordiazePOXIDE HCl 5 mg capsule0.31USD capsule
Chlordiazepoxide 5 mg capsule0.2USD capsule
Apo-Chlordiazepoxide 25 mg Capsule0.17USD capsule
Chlordiazepoxide 10 mg capsule0.14USD capsule
Apo-Chlordiazepoxide 10 mg Capsule0.11USD capsule
Apo-Chlordiazepoxide 5 mg Capsule0.07USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point236-236.5Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.
water solubility2000 mg/LYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.44HANSCH,C ET AL. (1995)
pKa4.8MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0199 mg/mLALOGPS
logP2.01ALOGPS
logP3.05ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)18.52ChemAxon
pKa (Strongest Basic)6.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity87.34 m3·mol-1ChemAxon
Polarizability30.97 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
References
Synthesis Reference

Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.

General References
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]
  2. Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. [PubMed:3089825 ]
  3. Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. [PubMed:458601 ]
  4. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373 ]
  5. Vozeh S: [Pharmacokinetic of benzodiazepines in old age]. Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. [PubMed:6118950 ]
External Links
ATC CodesN05BA02
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.9 KB)
Interactions
Drug Interactions
Drug
AminophyllineThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Aminophylline.
AprepitantThe serum concentration of Chlordiazepoxide can be increased when it is combined with Aprepitant.
AzelastineChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Chlordiazepoxide.
BexaroteneThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Bosentan.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
BuprenorphineChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Cimetropium BromideChlordiazepoxide may increase the anticholinergic activities of Cimetropium Bromide.
ClozapineThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Clozapine.
ConivaptanThe serum concentration of Chlordiazepoxide can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Dabrafenib.
DasatinibThe serum concentration of Chlordiazepoxide can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Deferasirox.
DisulfiramThe serum concentration of Chlordiazepoxide can be increased when it is combined with Disulfiram.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
DyphyllineThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Dyphylline.
EluxadolineChlordiazepoxide may increase the activities of Eluxadoline.
EthanolChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FluconazoleThe metabolism of Chlordiazepoxide can be decreased when combined with Fluconazole.
FosaprepitantThe serum concentration of Chlordiazepoxide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Chlordiazepoxide.
Fusidic AcidThe serum concentration of Chlordiazepoxide can be increased when it is combined with Fusidic Acid.
Gamma Hydroxybutyric AcidChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.
HydrocodoneChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
IdelalisibThe serum concentration of Chlordiazepoxide can be increased when it is combined with Idelalisib.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Chlordiazepoxide.
IvacaftorThe serum concentration of Chlordiazepoxide can be increased when it is combined with Ivacaftor.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlordiazepoxide.
LuliconazoleThe serum concentration of Chlordiazepoxide can be increased when it is combined with Luliconazole.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
MethadoneChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethotrimeprazineChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MetyrosineChlordiazepoxide may increase the sedative activities of Metyrosine.
MifepristoneThe serum concentration of Chlordiazepoxide can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
MirtazapineChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Mitotane.
MorphineThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
NelfinavirThe metabolism of Chlordiazepoxide can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Chlordiazepoxide can be increased when it is combined with Netupitant.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chlordiazepoxide.
OrphenadrineChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PalbociclibThe serum concentration of Chlordiazepoxide can be increased when it is combined with Palbociclib.
ParaldehydeChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Chlordiazepoxide.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlordiazepoxide.
PramipexoleChlordiazepoxide may increase the sedative activities of Pramipexole.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Chlordiazepoxide.
RamosetronChlordiazepoxide may increase the activities of Ramosetron.
RopiniroleChlordiazepoxide may increase the sedative activities of Ropinirole.
RotigotineChlordiazepoxide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlordiazepoxide.
SiltuximabThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Chlordiazepoxide can be increased when it is combined with Simeprevir.
Sodium oxybateChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
St. John's WortThe serum concentration of Chlordiazepoxide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Chlordiazepoxide can be increased when it is combined with Stiripentol.
SuvorexantChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.
TeduglutideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Teduglutide.
ThalidomideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TheophyllineThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Theophylline.
TocilizumabThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Tocilizumab.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Chlordiazepoxide.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Chlordiazepoxide.
YohimbineThe therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Yohimbine.
ZolpidemChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 03, 2014 16:54